TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in overall postprandial BSGM Gastric Alimetry Rhythm Index (GA-RI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of Recommended PTSD Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in resilience as assessed by Connor-Davidson Resilience Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in safety/IPV experience(s) as assessed by the Conflict Tactics Scale-2
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in help-seeking
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: SVD progression as measured by decline in global cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in falls frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life in YA Cancer Survivors - EORTC-QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life in YA Cancer Survivors - FACT-G
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of participants with Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in patient opioid-related risks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ki-67
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Completion of radiotherapy schedule
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Participants with Treatment Diagnostic Laparoscopy assessed by Predictive Index Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants with Treatment Diagnostic Laparoscopy assessed by utilizing machine learning and computer vision models to analyze images and videos
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Seropositive rates of varicella antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMT of varicella antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sample integrity of Tasso+™
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Testing accuracy of Tasso+™
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of Tasso+™
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRD negative complete remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type, incidence and severity of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Survival free from ventricular arrhythmia recurrence
Endpoint domain: Mortality/survival
Primary endpoint: POP-Q measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Pelvic Organ Prolapse / Incontinence Sexual
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Angiographic Revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DTG minimum concentrations (Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Early Onset Sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Broad Acceptance Scale (BAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Personal Acceptance Scale (PAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Duodenal mucosal inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence and severity of Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: GERD Health Related Quality of Life questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reflux Severity Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete and Partial responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft tissue to bone healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of TEAEs (including TESAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of TEAEs (including TESAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: ORR by PCWG3 guideline based on Investigator review
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PSA50 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Best overall PSA response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Impella ECP-related major vascular complications
Endpoint domain: Adverse events/effects
Primary endpoint: Impella ECP-related Major Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Failure of the Nasal High Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Severity of Psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frontal Midline Theta Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anxiety and Depression Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum tolerated dose (MTD) of RLY-2608 as a single agent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of RLY-2608 in combination with fulvestrant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of RLY-2608 in combination with fulvestrant and a CDK 4/6 inhibitor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with adverse events and serious adverse events of RLY-2608 as a single agent
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Adverse Device Events (ADEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Serious Adverse Device Events (SADEs)
Endpoint domain: Adverse events/effects
Primary endpoint: 10-Meter Walk Test (10MWT) at Self-Selected walking Velocity (SSV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting State Functional Connectivity (rsFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Task-induced fMRI activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined retention and treatment failure outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall reduction in the number of new brain lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Change in Loneliness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the Performance of Upper Limb (PUL) 2.0 score from baseline to Week 25
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Performance of Upper Limb (PUL) 2.0 score from Week 25 to Week 49
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Performance of Upper Limb (PUL) 2.0 score from baseline to Week 49
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants Using a COVID-19 Test
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Corneal fluorescein staining (CFS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Glycated Hemoglobin- HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Glucose time in range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in daily insulin Bolus score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recurrent anterior prolapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of data extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with clinically significant changes in physical examination results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional MRI (fMRI) responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with abnormal vital signs
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with abnormal ECG readings
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with abnormal physical examination findings
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with abnormal haematology, clinical chemistry, coagulation, and urinalysis values
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with local reactions at the injection site
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with abnormal findings on the Columbia-Suicide Severity Ratings Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to ipsilateral breast tumor recurrence (IBTR)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants with Dose-limiting Toxicities (DLTs) in Cycle 1
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Overall Objective Tumor Responses (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of visceral fat content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of subjects who complete 4 consecutive weeks of DR-18
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Survival at 2 years free of disabling stroke, reoperation, or worsening HF
Endpoint domain: Mortality/survival
Primary endpoint: Wound Status Index (WSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline to Week 16 in N-terminal pro-brain natriuretic peptide (NT-proBNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of participants with one or more adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who discontinued study drug due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with overall success at Test-of-Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with Treatment-Emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of Major Structural Birth Defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in C-peptide concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants Who Completed 4 Cycles of Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Surgical specimen margin status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: CLA-IGA-R erythema score of 0 or 1 with at least a 2-point reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 70% reduction in CLASI-A score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal residual disease (MRD) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants who achieved clinical response per the Pediatric Crohn's Disease Activity Index (PCDAI) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of endoscopic response at Week 64
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eczema Area and Severity Index 75 (EASI75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Investigator's Global Assessment Treatment Success (IGA-TS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in HIV testing uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two-year real-world overall survival (rwOS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of Treatment-emergent Adverse Events (TEAEs)/Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Preload dependence risk evaluated by ROC AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Functional Assessment of Cancer Therapy Questionnaire for Breast Cancer (FACT-B+4) PRO Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Quality of Life Measure for Limb Lymphoedema (LYMQOL) Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Lymphedema rate as measured by L-DEX Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with adequate conditioned pain modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with normal temporal summation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CAPS-5 total severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Clinical pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Participants with live birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Improvement of Fibrosis ≥1 Stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: MASH/NASH Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Relative Change in Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Who Achieve Body Weight Reduction Greater Than or Equal to 5 Percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effectiveness of the Silver II Non-Woven Dressing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients That Completed Their Rural Home Hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of clinical trial participation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Comfort levels during perianesthesia
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tolerability of TMS
Endpoint domain: Adverse events/effects
Primary endpoint: Linear millimeters of molar tooth movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tooth angulation as measured radiographically
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Adverse Events (MAE) at 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Fear extinction learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extinction retrieval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in 6-Minute Walk Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periodontal pocket depth changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact on dopamine receptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in estimated GFR (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean Asthma Control Questionnaire Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sunburn cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: MMP-9 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thymine dimer expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of the LiquiBand FIX8 OHMF device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: interparental emotional security
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: family emotional security
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: externalizing problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Y-BOCS-II Severity Scale total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of the submandibular glands on PET-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of the lacrimal glands on PET-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hearing Handicap Inventory for Adults (HHIA) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: First diagnosis of gonorrhea at cervical or anorectal sites
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment Related Adverse Event (TRAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in soft drusen volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digitization accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Adverse Events Grade 3 and 4
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility as assessed by the number of participants included and who successfully completed the protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in acceptability of the treatment as assessed by the tDCS acceptability questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in safety of home-based tDCS treatment as assessed by the tDCS side effect questionnaire
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of proximal junctional kyphosis development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: EVs quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EVs size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EVs content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feces uric acid level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number (Incidence) of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom from MALE+POD
Endpoint domain: Adverse events/effects
Primary endpoint: Annual percentage of decline in Forced Vital Capacity (FVC, %)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Annual decline in Diffusing capacity of the Lungs for Carbon monoxide (DLco, %)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Annual decline in resting and exercise Oxygen Saturation (SpO2, %)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 14-day initial overall response to ITP treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month sustained overall response to ITP treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Pain - Short Form (Neuro-QOL™)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Analogue Scale (VAS) Pain Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wong-Baker FACES® Pain Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in serum Triglycerides (TG) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in serum High Density Lipoprotein Cholesterol (HDL-C) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Total Cholesterol (TC) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Low Density Lipoprotein Cholesterol (LDL-C) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Opioid use total
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of potentially actionable results based on pharmacogenomic (PGx) test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Brain Peak Width of Skeletonized Mean Diffusivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes